newsfilter
← Latest News
GlobeNewswire·

RenovoRx to Participate at the Canaccord Genuity MedTech Diagnostics and Digital Health & Services Forum

  • RenovoRx, Inc. (NASDAQ: RNXT) CEO Shaun Bagai & CFO Mark Voll will present at the Canaccord Genuity MedTech forum on November 11, 2026, in New York.
  • The presentation will review Q3 2026 financial results, commercial execution, & factors driving physician adoption of the Trans-Arterial Micro-Perfusion (TAMP™) platform.
  • The webcast is scheduled for 2:00 p.m. ET on November 11, 2026, with a replay available on the company's investor relations website.
  • RenovoCath is an FDA-cleared device for isolating blood flow & delivering fluids to peripheral vascular sites, including temporary vessel occlusion for arteriography & drug infusion.
  • The company generated approximately $1.1 million in RenovoCath sales in 2025 & reported record quarterly revenue of $909,000 in Q2 2026.
  • RenovoRx is expanding orders from high-volume National Cancer Institute-designated centers to increase RenovoCath adoption.
  • The Phase III TIGeR-PaC trial evaluating intra-arterial gemcitabine (IAG) via RenovoCath achieved full enrollment in August 2026.
  • Trial completion is expected in the first half of 2027, with topline data readout anticipated in the second half of 2027.
  • IAG has received Orphan Drug Designation for pancreatic & bile duct cancers, providing seven years of market exclusivity upon FDA approval.
  • The TAMP platform aims to deliver targeted therapies to tumor sites while minimizing systemic toxicities compared to intravenous therapy.